Angiodynamics released FY2025 Q4 earnings on July 15 Pre-Market (EST), actual revenue USD 80.16 M (forecast USD 74.26 M), actual EPS USD -0.1502 (forecast USD -0.2)

Brief Summary

AngioDynamics reported Q4 2025 earnings with revenue of $80.16 million and an EPS of -$0.1502, both exceeding market expectations.

Impact of The News

AngioDynamics’ Q4 2025 financial results show a revenue of $80.16 million, surpassing the market’s expectation of $74.26 million. The reported EPS is -$0.1502, better than the anticipated -$0.2, indicating a smaller-than-expected loss. This positive performance is reflected in several key areas:

1. Revenue Breakdown:

• Thrombus Management: Q4 revenue increased by 45.6% year-over-year to $13 million and the total annual revenue increased marginally by 0.1% to $24.5 million LB filings.
• Medical Devices: Q4 revenue saw a 6.2% year-over-year growth, totaling $44.4 million LB filings.
• Auryon Platform: Q4 revenue rose by 19.7% to $15.6 million, with over $1 million in European sales following CE marking approval Motley Fool.
• AngioVac: Q4 revenue grew by 39.5% to $8.2 million, and AlphaVac revenue increased by 60.8% to $3.1 million Motley Fool.

2. Financial Indicators:

• Adjusted EBITDA for Q4 2025 was $3.4 million, compared to $1.5 million in Q4 2024, showing significant improvement despite tariff pressures Motley Fool.
• Free cash flow in Q4 2025 was $16.2 million, attributed to operational efficiency efforts Reuters.

3. Future Guidance:

• For FY 2026, AngioDynamics projects an adjusted EPS loss between $0.25 and $0.35 and net sales between $305 million and $310 million, slightly below market expectations of a $0.23 loss per share and $304.86 million in sales rttnews.

In summary, AngioDynamics’ positive Q4 results, driven by strong revenue growth across major product lines and improved operational efficiency, suggest potential for continued business development. However, the future guidance indicates cautious optimism with expectations of continued losses but stable revenue growth. The company’s efforts in operational efficiency and strategic product expansions could play a crucial role in mitigating losses and improving margins moving forward.